MX379481B - Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer - Google Patents

Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer

Info

Publication number
MX379481B
MX379481B MX2017012419A MX2017012419A MX379481B MX 379481 B MX379481 B MX 379481B MX 2017012419 A MX2017012419 A MX 2017012419A MX 2017012419 A MX2017012419 A MX 2017012419A MX 379481 B MX379481 B MX 379481B
Authority
MX
Mexico
Prior art keywords
liv
humanized antibodies
same
treat cancer
antibodies
Prior art date
Application number
MX2017012419A
Other languages
English (en)
Inventor
Albina Nesterova
Django Sussman
Maria Leia Smith
William Arthur
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MX379481B publication Critical patent/MX379481B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo humanizados que comprenden una región variable de cadena pesada madura que tiene una secuencia de aminoácidos que comprende la SEQ ID NO: 10 y una región variable de cadena ligera madura que tiene una secuencia de aminoácidos que comprende la SEQ ID NO: 15. Los anticuerpos son útiles para el tratamiento y diagnóstico de varios cánceres.
MX2017012419A 2010-12-06 2011-12-06 Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer MX379481B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42029110P 2010-12-06 2010-12-06
US201161446990P 2011-02-25 2011-02-25
PCT/US2011/063612 WO2012078688A2 (en) 2010-12-06 2011-12-06 Humanized antibodies to liv-1 and use of same to treat cancer

Publications (1)

Publication Number Publication Date
MX379481B true MX379481B (es) 2025-03-11

Family

ID=46207694

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017012419A MX379481B (es) 2010-12-06 2011-12-06 Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer
MX2013006365A MX351027B (es) 2010-12-06 2011-12-06 Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
MX2020010639A MX2020010639A (es) 2010-12-06 2013-06-06 Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2013006365A MX351027B (es) 2010-12-06 2011-12-06 Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
MX2020010639A MX2020010639A (es) 2010-12-06 2013-06-06 Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.

Country Status (25)

Country Link
US (6) USRE48959E1 (es)
EP (4) EP3461847B1 (es)
JP (6) JP6105481B2 (es)
KR (5) KR102198189B1 (es)
CN (1) CN103533957B (es)
AU (4) AU2011338480B8 (es)
BR (2) BR112013013781A2 (es)
CA (2) CA2819038C (es)
CY (3) CY1118874T1 (es)
DK (3) DK3461847T3 (es)
ES (3) ES2719548T3 (es)
HR (1) HRP20170567T1 (es)
HU (3) HUE043355T2 (es)
IL (4) IL299837A (es)
LT (1) LT2648752T (es)
MX (3) MX379481B (es)
NZ (1) NZ611468A (es)
PL (3) PL3461847T3 (es)
PT (3) PT3461847T (es)
RS (1) RS55843B1 (es)
RU (1) RU2608646C2 (es)
SG (3) SG10201912646UA (es)
SI (3) SI2648752T1 (es)
WO (1) WO2012078688A2 (es)
ZA (1) ZA201303803B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX379481B (es) * 2010-12-06 2025-03-11 Seagen Inc Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN105007941B (zh) 2012-12-27 2019-01-25 赛诺菲 抗-lamp1抗体和抗体药物偶联物及其用途
MX2016001165A (es) * 2013-07-31 2016-06-29 Amgen Inc Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
CA3187392A1 (en) 2013-10-15 2015-04-23 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
JP6716461B2 (ja) 2014-02-17 2020-07-01 シアトル ジェネティックス， インコーポレイテッド 親水性抗体−薬物コンジュゲート
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US20190194338A1 (en) * 2016-02-17 2019-06-27 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
KR20220157515A (ko) 2016-03-15 2022-11-29 씨젠 인크. Liv1-adc와 화학요법제를 사용한 병용 요법
MA43835A (fr) 2016-03-25 2018-11-28 Seattle Genetics Inc Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
KR20240010534A (ko) 2016-08-09 2024-01-23 씨젠 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
EA201891851A1 (ru) * 2016-09-16 2019-04-30 Сиэтл Дженетикс, Инк. Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
EA201990890A1 (ru) 2016-10-18 2019-10-31 Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
MX2019010804A (es) 2017-03-15 2020-01-23 Silverback Therapeutics Inc Compuestos de benzazepina, conjugados y usos de los mismos.
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
US11305224B2 (en) 2017-04-18 2022-04-19 3M Innovative Properties Company Air filter media with post-pleat-deposited sorbent particles
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
JP2020532543A (ja) * 2017-09-02 2020-11-12 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用
CR20200145A (es) * 2017-09-02 2020-08-03 Abbvie Inc Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
KR20200090838A (ko) * 2017-12-01 2020-07-29 시애틀 지네틱스, 인크. 유방암 치료를 위한 인간화된 항-liv1 항체
IL276546B2 (en) 2018-02-20 2024-08-01 Seagen Inc Hydrophobic auristatin F compounds and their conjugates
US20220048895A1 (en) 2018-09-12 2022-02-17 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
SG11202101980VA (en) 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
AU2019337652A1 (en) 2018-09-12 2021-03-18 Silverback Therapeutics, Inc. Antibody conjugates of toll-like receptor agonists
WO2020056194A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
CN113015750A (zh) * 2018-11-07 2021-06-22 克里斯珀医疗股份公司 抗liv1免疫细胞癌症疗法
US20220306727A1 (en) 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
GB201908208D0 (en) * 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent
EP4004046A1 (en) * 2019-07-22 2022-06-01 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
BR112022002720A2 (pt) 2019-08-15 2022-10-11 Silverback Therapeutics Inc Formulações de conjugados de benzazepinas e usos das mesmas
CA3151322A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
TW202133887A (zh) 2019-12-09 2021-09-16 美商西健公司 使用liv1-adc及pd-1拮抗劑之組合療法
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
IL299508A (en) 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Anti-asgr1 antibody conjugates and uses thereof
CA3197158A1 (en) * 2020-09-28 2022-03-31 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
KR20230158005A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
JP2024516970A (ja) * 2021-05-07 2024-04-18 サーフィス オンコロジー， エルエルシー 抗ｉｌ－２７抗体及びその使用
WO2023288236A1 (en) 2021-07-14 2023-01-19 Seagen Inc. Antibody masking domains
US20240376200A1 (en) 2021-09-24 2024-11-14 Seagen Inc. Improved Antibody Masking Domains
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
KR20250044188A (ko) 2022-05-12 2025-03-31 하이난 심시어 자이밍 파마슈티컬 컴퍼니 리미티드 캄프토테신계 유도체 및 리간드-약물 접합체
WO2024109944A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 抗liv-1抗体、其药物偶联物及其医药用途
JP2026506563A (ja) 2023-02-07 2026-02-25 ラノバ メディシンズ リミテッド Ｌｉｖ－１を標的とする抗体およびその使用
EP4682168A1 (en) 2023-03-15 2026-01-21 BioRay Pharmaceutical Co., Ltd. Anti-liv-1 antibody and anti-liv-1 antibody-drug conjugate, and pharmaceutical use thereof
WO2025021118A1 (zh) * 2023-07-25 2025-01-30 海南先声再明医药股份有限公司 配体-药物偶联物及其偶联连接子
WO2025146137A1 (zh) * 2024-01-05 2025-07-10 海南先声再明医药股份有限公司 抗liv-1抗体药物偶联物及其用途
WO2025146128A1 (zh) * 2024-01-05 2025-07-10 海南先声再明医药股份有限公司 抗liv-1的抗体及其用途
CN120040587B (zh) * 2025-04-27 2025-08-08 上海宏成药业有限公司 抗liv-1抗体或其抗原结合片段及其用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ES2129454T3 (es) 1991-08-22 1999-06-16 Becton Dickinson Co Procedimientos y composiciones de tratamientos de cancer y pronostico de reacciones a los indicados tratamientos.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
CA2132500A1 (en) 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
WO1998018945A1 (en) 1996-10-31 1998-05-07 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
WO1998034118A1 (en) 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
EP1027444A1 (en) 1997-10-31 2000-08-16 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999025877A1 (en) 1997-11-18 1999-05-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
EP1042360A2 (en) 1997-12-24 2000-10-11 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
JP3422776B2 (ja) 1998-08-04 2003-06-30 ダイアデクスアス・インコーポレーテッド 乳癌を診断、監視、病期決定、造影及び治療する新規な方法
ATE386804T1 (de) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
MXPA01007845A (es) 1999-02-05 2004-06-22 Samsung Electronics Co Ltd Metodo para la recuperacion de la textura de imagenes y aparato para el mismo.
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6762020B1 (en) 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US7285382B2 (en) 2000-01-25 2007-10-23 Genentech, Inc. Compositions and methods for treatment of cancer
AU2001264099A1 (en) 2000-06-13 2001-12-24 University College Cardiff Consultants Ltd. Zinc transporters
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003000012A2 (en) 2001-06-21 2003-01-03 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
KR101104655B1 (ko) 2002-03-08 2012-01-13 애보트 바이오테라퓨틱스 코포레이션 암 항원 ｔｍｅｆｆ２ 에 대한 항체 및 이의 용도
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
MXPA05007940A (es) * 2003-01-27 2007-06-14 Biogen Idec Inc Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
KR20050010267A (ko) 2003-07-18 2005-01-27 삼성전자주식회사 식각장치
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
US20060222653A1 (en) * 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
AU2006287416A1 (en) 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
EP2012827A2 (en) 2006-04-13 2009-01-14 Novartis Vaccines and Diagnostics, Inc. Methods of treating, diagnosing or detecting cancer
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
JP2010527916A (ja) 2007-04-23 2010-08-19 ワイス・エルエルシー Ｉｌ−１３関連障害を治療する方法および組成物ならびにその治療をモニターする方法
EP2641919A3 (en) * 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
ES2458541T5 (en) 2008-05-02 2025-08-04 Seagen Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
RU2011101378A (ru) 2008-06-16 2012-07-27 Сайвидон Дайагностикс Гмбх (De) Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии
WO2010045234A1 (en) 2008-10-14 2010-04-22 University Of Louisville Research Foundation, Inc. Methods of optimizing treatment of estrogen-receptor positive breast cancers
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
US20110165566A1 (en) 2009-07-09 2011-07-07 Wittliff James L Methods of optimizing treatment of breast cancer
CN102597268B (zh) 2009-09-03 2017-09-22 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
MX379481B (es) 2010-12-06 2025-03-11 Seagen Inc Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer
WO2012125712A2 (en) 2011-03-14 2012-09-20 Respira Health, Llc Lung tumor classifier for current and former smokers
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
KR20220157515A (ko) 2016-03-15 2022-11-29 씨젠 인크. Liv1-adc와 화학요법제를 사용한 병용 요법
KR20200090838A (ko) 2017-12-01 2020-07-29 시애틀 지네틱스, 인크. 유방암 치료를 위한 인간화된 항-liv1 항체
CN113015750A (zh) 2018-11-07 2021-06-22 克里斯珀医疗股份公司 抗liv1免疫细胞癌症疗法
GB201908208D0 (en) 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent

Also Published As

Publication number Publication date
HUE043355T2 (hu) 2019-08-28
US20200165335A1 (en) 2020-05-28
CA2819038C (en) 2023-10-17
EP2648752B1 (en) 2017-02-15
USRE48959E1 (en) 2022-03-08
PT2648752T (pt) 2017-03-28
IL299837A (en) 2023-03-01
JP2023011709A (ja) 2023-01-24
AU2017203851B2 (en) 2019-01-31
KR20200145867A (ko) 2020-12-30
US20130259860A1 (en) 2013-10-03
PL3156420T3 (pl) 2019-08-30
ES2620264T3 (es) 2017-06-28
KR101993921B1 (ko) 2019-06-28
WO2012078688A3 (en) 2012-08-23
LT2648752T (lt) 2017-04-10
US20160185858A1 (en) 2016-06-30
PT3461847T (pt) 2020-12-24
CY1123883T1 (el) 2022-03-24
MX351027B (es) 2017-09-28
IL273607B2 (en) 2023-06-01
EP3461847B1 (en) 2020-09-23
CN103533957B (zh) 2016-06-22
US9783608B2 (en) 2017-10-10
SI3461847T1 (sl) 2021-03-31
RU2608646C2 (ru) 2017-01-23
IL226754B (en) 2018-10-31
AU2019202530B2 (en) 2021-04-01
WO2012078688A2 (en) 2012-06-14
CN103533957A (zh) 2014-01-22
EP3461847A1 (en) 2019-04-03
US20240247059A1 (en) 2024-07-25
JP2019073515A (ja) 2019-05-16
SI2648752T1 (sl) 2017-06-30
RU2013130609A (ru) 2015-01-20
JP2014506120A (ja) 2014-03-13
MX2020010639A (es) 2020-10-28
DK3156420T3 (en) 2019-04-29
EP3156420B1 (en) 2019-02-20
EP2648752A2 (en) 2013-10-16
IL261900A (en) 2018-10-31
RS55843B1 (sr) 2017-08-31
PL3461847T3 (pl) 2021-07-05
ES2719548T3 (es) 2019-07-11
AU2011338480A8 (en) 2017-03-23
PL2648752T3 (pl) 2017-07-31
JP2017149717A (ja) 2017-08-31
BR122021020513B1 (pt) 2022-10-25
EP3786185A1 (en) 2021-03-03
US9228026B2 (en) 2016-01-05
PT3156420T (pt) 2019-05-27
AU2021204473B2 (en) 2024-07-18
HRP20170567T1 (hr) 2017-06-16
AU2021204473A1 (en) 2021-07-29
AU2011338480A1 (en) 2013-06-13
JP2024178209A (ja) 2024-12-24
ES2842895T3 (es) 2021-07-15
MX2013006365A (es) 2013-08-15
BR112013013781A2 (pt) 2016-09-13
AU2011338480B2 (en) 2017-03-16
JP7166384B2 (ja) 2022-11-07
AU2011338480B8 (en) 2017-03-23
SI3156420T1 (sl) 2019-05-31
KR20230057485A (ko) 2023-04-28
AU2017203851A1 (en) 2017-06-22
CA3211246A1 (en) 2012-06-14
KR20190076068A (ko) 2019-07-01
HUE031726T2 (en) 2017-07-28
DK3461847T3 (da) 2020-12-14
JP6869218B2 (ja) 2021-05-12
JP6453924B2 (ja) 2019-01-16
SG10201510041QA (en) 2016-01-28
EP3461847A8 (en) 2021-04-14
CY1121546T1 (el) 2020-05-29
EP2648752A4 (en) 2015-05-20
JP2021106599A (ja) 2021-07-29
AU2019202530A1 (en) 2019-05-02
KR20130135884A (ko) 2013-12-11
KR20220011811A (ko) 2022-01-28
NZ611468A (en) 2015-06-26
KR102198189B1 (ko) 2021-01-05
ZA201303803B (en) 2014-07-30
IL273607A (en) 2020-05-31
HUE052806T2 (hu) 2021-05-28
EP3156420A1 (en) 2017-04-19
JP6105481B2 (ja) 2017-03-29
CY1118874T1 (el) 2018-01-10
SG10201912646UA (en) 2020-02-27
SG190938A1 (en) 2013-07-31
US20180079810A1 (en) 2018-03-22
CA2819038A1 (en) 2012-06-14
DK2648752T3 (en) 2017-03-27

Similar Documents

Publication Publication Date Title
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
MX2023000889A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
IN2014KN00848A (es)
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
EA201201000A1 (ru) Способы лечения колоректального рака
TN2015000396A1 (en) Antibody drug conjugates
EA201200999A1 (ru) Способы лечения рака молочной железы
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
NZ611785A (en) Anti-notch1 antibodies
PL2550296T3 (pl) Przeciwciała monoklonalne w leczeniu nowotworów
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
NZ700274A (en) Anti-pdgf-c antibodies
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.